The Pharma Data

OCTOBER 16, 2020

As pharma companies search for solutions to avoid cancelling or delaying clinical trials, virtualizing trials are fast becoming commonplace during the Covid-19 pandemic. In vitro antiviral technology proves effective against SARS-CoV-2 in human airway infection model.

In-Vitro 52

In-Vitro Clinical Trials Clinical Trials Trials 52

pharmaphorum

FEBRUARY 13, 2022

Quris’ BioAI safety prediction platform – which is based on human tissue samples on chips, nanosensors and machine learning – will be compared to traditional in vitro and in vivo laboratory techniques for spotting toxicity. The post Merck will assess Quris’ AI ‘patient-on-a-chip’ drug safety appeared first on.

Drugs 98

Drugs In-Vivo In-Vitro Pharma Companies 98

pharmaphorum

DECEMBER 1, 2022

Exploring the implementation of complex in-vitro models for drug development. The pharmaceutical industry globally is realising the growing potential of in vitro tissue models for drug discovery, pathology modelling and validation, safety and toxicity. Billion by 2028. Billion by 2028. Event Hashtag: #3DCellCulture2023.

In-Vitro 52

In-Vitro Scientist Engineer Gene Therapy 52

pharmaphorum

JANUARY 18, 2022

Developing Complex, Translatable and Physiologically-Relevant Cellular Models in vitro. Key Benefits of Attending: • Discuss the uses of advanced cell technologies to construct in vitro models of human tissues. Uncover the major benefits of 3D modelling in enhancing clinical translation and predictability. Who Should Attend?

In-Vitro 52

In-Vitro Engineer Drugs Pharma Companies 52

pharmaphorum

OCTOBER 12, 2020

Over the past few years, 3D Cell Culture has gained momentum within the pharmaceutical industry due to the benefits that this model offers for in vitro applications patient-derived tissues, drug discovery, predictivity and validation, and safety and toxicity. 3D-cellculture.com/PR1. . 3D-cellculture.com/PR1. 3D Cell Culture 2020.

In-Vitro 52

In-Vitro Development Pharma Companies Engineer 52

XTalks

OCTOBER 1, 2020

To gain insight into the motivations, steps and experiences involved in an academia to industry — or vice versa — transition, Xtalks spoke to several leading scientists and entrepreneurs in pharma and biotech who successfully transitioned from academic positions to leadership roles in industry settings. Key Moments.

Scientist 52

Scientist In-Vitro Research Life Science 52

pharmaphorum

JULY 6, 2022

A Franco-German joint venture company – Aurobac Therapeutics – has been formed to try to tackle the rising threat of antimicrobial resistant (AMR) infections. It’s the latest in a series of actions taken by the drug industry to try to reverse the mass exodus of companies from antimicrobials R&D over the last few decades.

In-Vitro 59

In-Vitro Development Pharma Companies Drugs 59